(Total Views: 493)
Posted On: 05/15/2020 3:52:55 AM
Post# of 9144
A partnership arrangement would require too long for the exigent circumstances
same with a sale- unless NNLX is willing to be taken for a ride-and nothing in their past indicates they would succumb to such a high pressure duress sale
the dd for either usually takes many months-involving sometimes difficult discounted future cash flow projections due to unknowns etc(we've seen throughout the virus that secular attempts to predict its course are highly erroneous due to unknowns)
and due to NNLX's small size would subject NNLX to an unfair arrangement with a much larger company -something I'm sure NNLX has experienced in negotiations before and no doubt doesn't want to experience again
NNLX- despite having the tech- doesnt have the resources for the necessary large scale production
thus -licensing is likely the fastest best option near term and should guarantee NNLX good income/royalties which would allow NNLX to pursue other expansions/configurations based on the N-assay
given the 33 patents NNLX had as of 2014 as per the website and the many more since,it seems that invention is NNLX's forte-compared to very little experience with production-its usually best to stick to ones strengths -so many variants for many different applications could be configured and licensed
NNLX's website lists a wide variety of potential applications for the N-assay-not just the 3 applications presented by Dr Faro at the 2016 conference where his presentation won awards-and not just the applications being worked out with the UK company
btw, since the N-assay is already patented and this application is another expansion or variant of the N assay-if some company tried to steal or copy this or another application of the N-assay -it seems it should be relatively simple to show the origin of such a rival companies tech to be based on NNLX patented tech (the N-assay) and NNLX's patent pending tech(the particular COvid 19 application)
same with a sale- unless NNLX is willing to be taken for a ride-and nothing in their past indicates they would succumb to such a high pressure duress sale
the dd for either usually takes many months-involving sometimes difficult discounted future cash flow projections due to unknowns etc(we've seen throughout the virus that secular attempts to predict its course are highly erroneous due to unknowns)
and due to NNLX's small size would subject NNLX to an unfair arrangement with a much larger company -something I'm sure NNLX has experienced in negotiations before and no doubt doesn't want to experience again
NNLX- despite having the tech- doesnt have the resources for the necessary large scale production
thus -licensing is likely the fastest best option near term and should guarantee NNLX good income/royalties which would allow NNLX to pursue other expansions/configurations based on the N-assay
given the 33 patents NNLX had as of 2014 as per the website and the many more since,it seems that invention is NNLX's forte-compared to very little experience with production-its usually best to stick to ones strengths -so many variants for many different applications could be configured and licensed
NNLX's website lists a wide variety of potential applications for the N-assay-not just the 3 applications presented by Dr Faro at the 2016 conference where his presentation won awards-and not just the applications being worked out with the UK company
btw, since the N-assay is already patented and this application is another expansion or variant of the N assay-if some company tried to steal or copy this or another application of the N-assay -it seems it should be relatively simple to show the origin of such a rival companies tech to be based on NNLX patented tech (the N-assay) and NNLX's patent pending tech(the particular COvid 19 application)
(3)
(0)
